Home » Stocks » NVS

Novartis AG (NVS)

Stock Price: $91.30 USD 1.06 (1.17%)
Updated December 4, 12:36 PM EST - Market open

NVS Stock Price Chart

Key Info

Market Cap 225.24B
Revenue (ttm) 48.68B
Net Income (ttm) 11.73B
Shares Out 2.31B
EPS (ttm) 3.09
PE Ratio 29.58
Forward PE n/a
Dividend $3.09
Dividend Yield 3.38%

Stock Quote

Trading Day December 4
Last Price $91.30
Previous Close $90.24
Change ($) 1.06
Change (%) 1.17%
Day's Open 91.06
Day's Range 90.98 - 91.52
Day's Volume 449,122
52-Week Range 70.67 - 99.01

NVS Stock News

PRNewsWire - 3 days ago

EAST HANOVER, N.J., Dec. 1, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (...

Seeking Alpha - 3 days ago

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...

Other stocks mentioned: ALLO, ATRA, BMY, CLLS, CRSP, GILD, PFE
Seeking Alpha - 1 week ago

Novartis' shares are inexpensive and trade at a discount to its historic valuation range. Shares offer a solid dividend yield of 3.5% at current prices.

Zacks Investment Research - 1 week ago

Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Benzinga - 1 week ago

On Tuesday, Swiss biopharma company Novartis AG (NYSE: NVS) announced a $2.5 billion share buyback program. The management also exhibited a heightened confidence level in its sales projections...

GlobeNewsWire - 1 week ago

Basel, November 24, 20 20 — Novartis is hosting today its annual Meet Novartis Management event giving investors and industry analysts the opportunity to meet with key executives across the co...

Seeking Alpha - 1 week ago

As dividend growth investors, we know that wide moat stocks make a good starting point, but it is just one of many considerations on our hunt for high-quality dividend growth stocks. The stock...

Other stocks mentioned: BAESY, BTI, DEO, LRLCY, NSRGY, RHHBY, SNY, TCEHY, UL, UN
Zacks Investment Research - 2 weeks ago

Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.

Other stocks mentioned: MESO
GlobeNewsWire - 2 weeks ago

Basel, November 19 , 20 20 — Novartis announced today that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture r...

GlobeNewsWire - 2 weeks ago

The digital press release with multimedia content can be accessed here:

GlobeNewsWire - 2 weeks ago

Basel, November 19 , 20 20 — Novartis today announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean p...

The Motley Fool - 2 weeks ago

Using traditional metrics, it seems in peril, but investors need to take a closer look in order to judge just how safe the payout is.

GlobeNewsWire - 3 weeks ago

The digital press release with multimedia content can be accessed here:

GlobeNewsWire - 4 weeks ago

Basel, November 6 , 20 20 — Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety o...

GlobeNewsWire - 4 weeks ago

Basel, November 5, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial,...

InvestorPlace - 1 month ago

Do you want to know how to invest in startups? Start by taking at look at these seven unicorn startups and their unique business models.

Other stocks mentioned: DOCU, PG, SQ, TWLO, V, ZM
GuruFocus - 1 month ago

Novartis AG (NYSE:NVS) is expanding its gene therapy footprint by acquiring a venture capital-backed company focusing on treating vision loss that can lead to blindness.

GlobeNewsWire - 1 month ago

The digital press release with multimedia content can be accessed here:

GlobeNewsWire - 1 month ago

Basel, October 30, 2020 — Novartis today announced the receipt of marketing authorization from Japan's Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and I...

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered...

Benzinga - 1 month ago

Novartis AG (NYSE: NVS) announced Wednesday it has received the license for global rights to develop, manufacture, and commercialize two antiviral therapies of Molecular Partners AG (OTC: MLLC...

GlobeNewsWire - 1 month ago

Basel, October 28 , 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular...

Seeking Alpha - 1 month ago

Novartis (NVS) CEO, Vas Narasimham on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 1 month ago

Novartis AG's (NVS) CEO Vas Narasimhan on Q3 2020 Results - Quick Version Earnings Call Transcript

Invezz - 1 month ago

Shares of Novartis (SIX: NOVN) fell almost 4% Tuesday after the Swiss pharmaceuticals company reported lower-than-expected sales in the third quarter.  Fundamental analysis: Higher income, low...

Zacks Investment Research - 1 month ago

Novartis' (NVS) third-quarter 2020 sales take a hit due to the coronavirus pandemic but earnings beat estimates.

Benzinga - 1 month ago

  Shares of Novartis (NYSE:NVS) decreased 1.6% in pre-market trading after the company reported Q3 results.

Bloomberg Markets and Finance - 1 month ago

Novartis CEO ‘Cautiously Optimistic' on Covid Impact in Fourth Quarter

Oct.27 -- Novartis Chief Executive Officer Vas Narasimhan discusses the business impact of Covid-19, the race for a vaccine, and the company's development of a coronavirus antibody treatment. ...

Investors Business Daily - 1 month ago

Novartis earnings beat third-quarter views while sales came in light. Full-year revenue guidance was in line for the Swiss drug giant.

GlobeNewsWire - 1 month ago

Basel, October 27 , 2020 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said:

CNBC Television - 1 month ago

Here's a preview of pharma earnings coming out this week

Geoff Meacham, Bank of America Securities biopharmaceuticals research analyst, joins "Squawk Box" to discuss the high profile earnings reports expected out of the pharmaceutical industry.

Other stocks mentioned: LLY, MRK, PFE
GlobeNewsWire - 1 month ago

Basel, October 26 , 20 20 — Novartis today announced positive Phase II interim analysis results for iptacopan (LNP023), an investigational oral treatment for C3 glomerulopathy (C3G), presented...

Zacks Investment Research - 1 month ago

Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.

GlobeNewsWire - 1 month ago

If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia.

Kiplinger - 1 month ago

Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best ...

Other stocks mentioned: BTI, NSRGY, NVO, RHHBY, SAP, SNY, UL, UN, VEA
Fast Company - 1 month ago

In a conversation with ‘Fast Company’ Editor-in-Chief Stephanie Mehta, Novartis CEO Vas Narasimhan explained why the world failed to respond to the pandemic—and how we can eventually get back ...

PRNewsWire - 2 months ago

EAST HANOVER, N.J., Oct. 3, 2020 /PRNewswire/ -- Novartis today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episod...

The Motley Fool - 2 months ago

A House committee has issued detailed reports about some of their drug price increases.

Other stocks mentioned: AMGN, MNK
Zacks Investment Research - 2 months ago

Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.

GlobeNewsWire - 2 months ago

Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvest...

GlobeNewsWire - 2 months ago

Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with t...

InvestorPlace - 2 months ago

Although it’s one of the major pharmaceuticals, Novartis didn’t directly jump into the vaccine race. That might have been the best move for Novartis stock.

Seeking Alpha - 2 months ago

Novartis: Finally In Position To Make Share Price Gains It Deserves

Reuters - 2 months ago

A Milan judge has seized 2.3 million euros ($2.7 million) from pharmaceutical multinational Novartis as part of a fraud investigation, a document seen by Reuters shows.

GlobeNewsWire - 2 months ago

 COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1

PRNewsWire - 2 months ago

EAST HANOVER, N.J., Sept. 16, 2020 /PRNewswire/ -- Today the Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and ...

GlobeNewsWire - 2 months ago

Basel, September 16, 2020 — Novartis today announced the pricing of a EUR 1.85 billion sustainability-linked bond (SLB), reinforcing its commitment to ESG principles and the 2025 Patient Acces...

Zacks Investment Research - 2 months ago

Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.

Zacks Investment Research - 2 months ago

Novartis (NVS) announces positive data on Beovu from an ongoing late-stage study for the DME indication.

GlobeNewsWire - 2 months ago

Basel, September 14, 2020 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP), has approved an update to the Beovu® (brolucizumab) Summary of Product Char...

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic are... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Nov 18, 1991
Employees
110,000
Stock Exchange
NYSE
Ticker Symbol
NVS
Full Company Profile

Financial Performance

In 2019, Novartis's revenue was $48.68 billion, an increase of 5.59% compared to the previous year's $46.10 billion. Earnings were $11.73 billion, a decrease of -6.97%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Novartis is 104.50, which is an increase of 14.46% from the latest price.

Price Target
$104.50
(14.46% upside)